Was Dr. Bunn Insensitive Or Just Efficient? FDA Imbroglio Points To Larger Problems
In Brief: ASTRO Officers Named; AACR Fellowships Available; NRC Won’t Revoke NIH License
FDA Likely To Change Procedures For Patient Interaction, Official Says
RPR Grant To NABCO Does Not Support Advocacy, Firm Says
ODAC Chairman: Time Was Tight For Meeting
Trending Stories
- Karen Knudsen to leave ACS
- A $150M gift enables City of Hope to establish $1M Stephenson Prize in pancreatic cancer research, build research program focused on the disease
- Factors outside CAR T-cell therapy are associated with increased risk of secondary cancers after the treatment, meta-analysis shows
Subgroup analysis suggests risk of secondary cancers after CAR T-cell therapy is similar to risk after other therapies - Jeffrey S. Weber, pioneering immunologist and melanoma expert at NYU, dies at 72
- Mace Rothenberg’s museum will tell the stories behind breakthroughs in medicine
- Melanoma investigators invite FDA to publicly discuss approval endpoints and crossover design
The agency accepts the invitation